Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10389707 | 0.87 | POLB (0.62) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10598558 | 0.86 | POLB (0.69) | POLBTP53MAPTKDM1AMAOA | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.85 | POLB (0.78) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL2560978 | 0.85 | POLB (0.64) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL6209756 | 0.84 | MGLL (0.68) | POLBTP53MAPTMAOAMAOB | |
| SCHEMBL4879134 | 0.84 | POLB (0.59) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL4879147 | 0.84 | POLB (0.59) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL29951102 | 0.84 | MGLL (0.68) | POLBTP53MAPTMAOAMAOB | |
| SCHEMBL1870929 | 0.84 | POLB (0.71) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL13359604 | 0.83 | MEN1 (0.56) | MAPTKDM1AMAOARCOR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080090884-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090884-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1615916-A1 | ANTIMICROBIAL 3.1.0 BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES | Pharmacia & Upjohn Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2004089943-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6355810-B1 | TREATMENT AND PREVENTION OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, ATHEROSCLEROSIS | ADVANCED MEDICINE, INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1083894-A1 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063994-A9 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999063994-A1 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5496834-A | PEPTIDE DERIVATIVES AS CATHEPSIN L INHIBITORS AND INHIBITORS OF BONE RESORPTION OR TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | POLB 979/4885TP53 4646/4885MAPT 4726/4885 |
| US-20080090884-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES | OXA1L, CYP51A1, CYP2C19 | POLB 754/4885TP53 4608/4885MAPT 4701/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | POLB 1544/4885TP53 340/4885MAPT 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.